March 15, 2020
Pfizer’s five-point plan to battle COVID-19
Chairman and CEO Albert Bourla Calls on Biopharma Industry to Collaborate on Combatting the Global Pandemic NEW YORK–(BUSINESS WIRE)–Pfizer today…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
March 13, 2020
IBM Watson Health and EBSCO partner up
IBM Watson Health and EBSCO Information Services Thursday announced a strategic collaboration aimed towards enhancing clinical decision support (CDS) and operations for healthcare providers and health systems.
March 12, 2020
Medicago produces a viable vaccine candidate for COVID-19
The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology Medicago’s platform…
March 11, 2020
Faller Packaging goes on tour with seminar
@augustfalleraugustfaller goes on tour with a seminar
March 5, 2020
Amunix nets $73M in Series A financing round
Amunix Pharmaceuticals, a tumor cancer-focused biopharmaceutical company has completed $73 million Series A financing round.
March 5, 2020
GenomSys moves to Biopôle in Lausanne
GenomSys has moved two of its teams to the BioPôle in Lausanne, to support the company’s growth and improve its accessibility to the Life Sciences community.
February 25, 2020
Moderna ships mRNA vaccine against coronavirus (mRNA-1273) for Phase 1 study
mRNA-1273 delivered from Company’s cGMP facility in 42 days from sequence selection CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical…
February 25, 2020
Akili Announces Publication of AKL-T01 ADHD Pivotal Study Results in the Lancet Digital Health
First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD…
January 28, 2020
Adverum Biotechnologies opens new HQ in Redwood City, San Francisco
Clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, Adverum Biotechnologies on Tuesday announced the opening of its new corporate headquarters at one of the largest biotechnology research complexes in the San Francisco Bay Area.
January 27, 2020
Affiris to proceed with P2study with lead treatment for Parkinson’s
AFFiRiS AG, a clinical-stage biopharmaceutical company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, will proceed with the preparations for the planned phase 2 study and confirms its intended initiation in the US and Europe in the second half of 2020.